Actively Recruiting
Testing Ruxolitinib with CHOP Chemotherapy for Adults with Untreated Nodal T-Follicular Helper Cell Lymphomas
Led by City of Hope Medical Center · Updated on 2026-06-05
20
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, side effects, and optimal dose of ruxolitinib combined with CHOP chemotherapy in treating patients with untreated nodal T-follicular helper TFH cell lymphoma. This phase I trial aims to determine how well this combination works and to assess the tolerability and preliminary effectiveness, including maintenance therapy with ruxolitinib monotherapy for responders. The study also explores survival outcomes and chemotherapy dose intensity in this patient population. Participants receive ruxolitinib orally twice daily for 21 days along with cyclophosphamide, doxorubicin, vincristine intravenously on day 1, and prednisone orally daily for 5 days per cycle, repeated every 21 days for up to six cycles. Patients who respond to this treatment and are not candidates for stem cell transplantation may continue with ruxolitinib maintenance therapy in 28-day cycles for up to 12 cycles, with the option to extend treatment for another 12 cycles if response remains stable. During the study, participants undergo various assessments including bone marrow biopsies, cardiac scans MUGA or echocardiography, blood tests, and PETCT imaging to monitor disease and treatment effects. Researchers will measure the maximum tolerated dose of ruxolitinib, frequency of side effects, response rates, and patient-reported outcomes. After treatment, patients are followed for up to five years to assess long-term safety and effectiveness.
CONDITIONS
Brief Title
Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here